Cost-Effectiveness Analysis of RS-61443 (Mycophenolate Mofetil) Treatment for Intractable Acute Rejection in Renal Transplantation Recipinets

DOI
  • Noguchi Nakae
    Department of Health Policy and Management, School of Medicine, Keio University
  • Ikeda Shunya
    Department of Health Policy and Management, School of Medicine, Keio University
  • Sakamaki Hiroyuki
    Department of Health Policy and Management, School of Medicine, Keio University
  • Uchida Kazuharu
    Department of Transplant Surgery, Nagoya Second Red Cross Hospital
  • Ikegami Naoki
    Department of Health Policy and Management, School of Medicine, Keio University

Bibliographic Information

Other Title
  • RS-61443(Mycophenolate Mofetil)の腎移植後の難治性急性拒絶反応の治療についての費用-効果分析

Search this article

Description

A cost-effectiveness analysis comparison of RS-61443 (mycophenolate mofetil), a new immunosuppressant and muromonab CD3 in patients with intractable acute rejection after renal transplantation was conducted. A clinical decision model was created based upon their use in Nagoya Second Red Cross Hospital.<BR>This study was analyzed from the payer's perspective. The cost data was obtained from the center based on what would be paid to the hospital according to the Health Insurance Price of April 1996. The survival of the graft at ninety days was used as an effectiveness endpoint. Expected cost-effective ratios per graft surviving at ninety days were 1,647,277 Yen for RS-61143, and 3,486,746 Yen for Muromonab CD3 for the baseline analysis. Thus, an 1,488,460 Yen cost-savings of RS-61443 was observed. Comprehensive sensitive analysis were done, such as drug efficacy rate in the initial treatment, rejection rate after the initial treatment, and graft loss rate. However, the cost-saving by RS-61443 continued to be found for all of these cases so that the model can be considered to be robust. In conclusion, RS-61443 treatment proved to be cost-effective in comparison with Muromonab CD3 for intractable acute rejection in renal transplantation.

Journal

  • Iryo To Shakai

    Iryo To Shakai 8 (1), 41-51, 1998

    The Health Care Science Institute

Keywords

Details 詳細情報について

Report a problem

Back to top